Resolves Yes if PTAB issues final written decision in IPR2025-xxxx concerning Amgen's Repatha patent. If it finds all claims unpatentable, resolves accordingly. If not decided by close, No decision.
Outcome verified from uspto.gov.
Trading on material non-public information is prohibited. Markets are for entertainment and informational purposes using free Pulse Credits — no real-money wagering. If you believe a participant has acted on inside information, please report it.
AI analysis is unavailable for this market right now.
